

EDUCATION

- 2010-2012 **UNIVERSITY OF MIAMI SCHOOL OF BUSINESS** Coral Gables, FL
Masters of Business Administration, Health Sector Management and Policy, 12/2012
Six Sigma Training; Champion Certificate, 12/04/2011
- 2003-2005 **UNIVERSITY OF MIAMI SCHOOL OF MEDICINE** Miami, FL
Clinical Scientists Training Program; Certificate, 08/18/2005
- 1986-1993 **JOHANN WOLFGANG GOETHE UNIVERSITÄT** Frankfurt/Main, Germany
EBERHARD KARLS UNIVERSITÄT Tübingen, Germany
JUSTUS LIEBIG UNIVERSITÄT Giessen, Germany
LUDWIG MAXIMILIANS UNIVERSITÄT Munich, Germany
Medicine, Degree and date conferred: Dr.med. (M.D.), 06/23/1993

EXPERIENCE

ACADEMIC

- 2002-present **UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE** Miami, FL
Current Interim Chief, Division of Nephrology (Sep 2013 – today)
Professor of Clinical Medicine
Medical Director, DaVita North Miami Dialysis Clinic
Medical Director, Jackson Memorial Hospital Chronic Kidney Disease Management Program
- 2007-2013 Associate Professor of Clinical Medicine
Director, Nephrology Fellowship Training Program (November 2007 - June 2013)
- 2006-2008 Co-Director, Clinical Research Section, Division of Nephrology
- 2006-2007 Associate Director, Nephrology Fellowship Training Program
- 2003-2007 Assistant Professor of Clinical Medicine
- 2002-2003 Instructor of Clinical Medicine
- 1999-2002 **JACKSON MEMORIAL HOSPITAL** Miami, FL
Residency & Fellowship, Internal Medicine/Nephrology
- 1998-1999 **UNIVERSITY OF MIAMI VASCULAR BIOLOGY INSTITUTE** Miami, FL
Postdoctoral Fellow and Postdoctoral Associate
- 1995-1997 **NATIONAL INSTITUTES FOR DIABETES, DIGESTIVE, AND KIDNEY DISEASES** Bethesda, MD
Postdoctoral Associate
- 1993-1997 **MEDIZINISCHE KLINIK I, KLINIKUM GROSSADERN, LUDWIG-MAXIMILIANS-UNIVERSITÄT**
Munich, Germany
Arzt im Praktikum and Assistenzarzt (Intern and Resident)

NON-ACADEMIC

- 2006-present **L & F HEALTH, LLC** Miami, FL
President
Expert medical services to the legal, insurance, and investment community, clinical training sessions, and clinical trial support
- 1998-1998 **IVAX CORPORATION** Miami FL
Scientific Associate

CERTIFICATIONS AND LICENSURES

- 2002 American Board of Internal Medicine (Nephrology)
Recertified in 2012
- 2001 American Board of Internal Medicine (Internal Medicine)
Recertified in 2011
- 2001 Medical License (Florida) – active

PROFESSIONAL MEMBERSHIPS

- 2009-2014 Training Program Directors Executive Committee, American Society of Nephrology (elected)
- 2007 Fellow, American College of Physicians
- 2005 Fellow, American Society of Nephrology

UNIVERSITY COMMITTEES

- 2012-present Founding Member, Academy of Educators
- 2013-present Member, Faculty Senate
- 2011-2012 Member, Faculty Senate
- 2010-2012 Chair, Miller School of Medicine Faculty Council Committee on Committees
- 2009-present Member, Miller School of Medicine Faculty Council
- 2007-present Chair, Nephrology Fellow Selection Committee
- 2006-2009 Information Resources Committee
- 2004-present Member, Internal Medicine Intern Selection Committee
- 2004-2007 Objective Structured Clinical Examination for third year medical students
- 2004-2005 Member, Institutional Review Board (A) / Medical Sciences Committee 1
- 2003-2007 Member, Nephrology Fellow Selection Committee

HONORS AND AWARDS

- Beta Gamma Sigma (honor society for business students and scholars), 5/2013
- Valedictorian Award, University of Miami School of Business, Health Sector Management and Policy Executive MBA, 2012
- Teaching Award, University of Miami, Division of Nephrology, 2004, 2005, 2006, 2009, 2011

RESEARCH EXPERIENCE

FEDERALLY-FUNDED RESEARCH PERFORMED

- 2009-present A Randomized, Double-blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis (Immune Tolerance Network Protocol# ITN034A1), local co-PI
- 2002-2004 Clonal Selection in Diabetic Nephropathy (NIDDK, R2DK63083-01)

PARTICIPATION IN INDUSTRY-SPONSORED AND UNFUNDED CLINICAL TRIALS

- 2011-2012 An open-label, non-randomized, parallel-group study to characterize and compare the pharmacokinetics, safety, and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in matched healthy control subjects: CAGO178C2104; PI: Preston, Richard; Role: Co-Investigator

- 2011-2012 A Phase 1, Open-Label, Parallel-Group Study to evaluate the Pharmacokinetics and Safety of a Single Oral Dose of TAK-875 50 mg in Subjects with Normal or Varying Degrees of Impaired Renal Function: Study Number: TAK-875_111; PI: Preston, Richard; Role: Co-Investigator; 02/28/2011
- 2010-2011 Effect of Severely Impaired Renal Function on the Pharmacokinetics of Ospemifene in Postmenopausal Women Protocol Number 15-50921; PI: Preston, Richard; Role: Co-Investigator
- 2010-2011 A Single-Dose Study to Investigate the Pharmacokinetics of MK-0859 in Subjects with Impaired Renal Function. Protocol 038-00; PI: Preston, Richard; Role: Co-Investigator
- 2009-2011 The effects of iron infusion on fibroblast growth factor 23 (FGF23) and phosphate metabolism in patients with chronic kidney disease.; PI: Gutierrez, Orlando; Role: Co-Investigator
- 2009-2011 A Single Dose Pharmacokinetic Study of F2695 in Subjects with Normal or Mild To Severe Impaired Renal Function Protocol LVM-PK-02; PI: Preston, Richard; Role: Co-Investigator
- 2009-2011 Pilot Translational Clinical Trial: Effects of the Dietary Supplement L-Glutamine on 24-hour Urine Protein Excretion in Patients with Proteinuric Renal Disease Pilot study UMDCP-2009-01; PI: Preston, Richard; Role: Co-Investigator; 3/9/09-2/21/11
- 2008-2010 A Randomized, Double-blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis Short Title: Treatment of SLE with CTLA4Ig Immune Tolerance Network Protocol#; local PI: Contreras, Gabriel; Role: Co-Investigator
- 2008-2010 Evaluation of alpha galactosidase in dried blood spots from patients with chronic kidney disease; PI: Reiser, Jochen; Role: Co-Investigator
- 2008-2011 FGF-23 Reduction in Predialysis Chronic Kidney Disease (CKD); PI: Wolf, Myles; Role: Co-Investigator; 8/5/08-5/10/11
- 2008-2008 Mechanism-of-Action Research Project in Association with Studies of Rituximab in Systemic Lupus Erythematosus (U2971g) and Lupus Nephritis (U2970g); Protocol # U3759g; Local PI: Lenz, Oliver
- 2008-2001 The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3/4; PI: Contreras, Gabriel; Role: Co-Investigator; 7/22/08-5/17/11
- 2008-2009 A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety Of Two Doses Of Ocrelizumab In Patients With WHO Or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus; Local PI: Lenz, Oliver
- 2007-2011 Survival of Lupus Nephritis in the South Florida Cohort Group: Predictors of Remission and Relapse; PI: Contreras, Gabriel; Role: Co-Investigator
- 2006-2011 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS, Class III or IV Lupus Nephritis: Protocol U2970g - LUNAR Study; Local PI: Oliver Lenz
- 2006-2007 A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared with Placebo; Local PI: Lenz, Oliver
- 2006-2008 A Phase III Study of the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis; Local PI: Lenz, Oliver
- 2005-2011 A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis; PI: Contreras, Gabriel; Role: Co-Investigator
- 2005-2009 Improving Outcomes and Quality of Life in Minorities with Chronic Kidney Disease; PI: Lenz, Oliver
- 2004-2006 Achieving KDOQI targets in the Chronic Kidney Disease Clinic; PI: Lenz, Oliver

PUBLICATIONS

Original Articles

1. Contreras G, Pagan J, Chokshi R, Virmani S, Diego JM, Byers P, Isakova T, Munoz Mendoza J, Nayer A, Contreras JR, Panama G, Lenz O, Carpintero M, Muchayi T, Roth D. Comparison of Mortality of ESRD Patients with Lupus by Initial Dialysis Modality. *Clin J Am Soc Nephrol*. 2014 Sep 4. pii: CJN.02500314. [Epub ahead of print]
2. Preston RA, Karim A, Dudkowski C, Zhao Z, Garg D, Lenz O, Sica DA. Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment. *Clin Pharmacokinet*. 52(5):347-358, 2013
3. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. *Clin J Am Soc Nephrol*. 8(6):1009-1018, 2013
4. Baig A, Ciril E, Contreras G, Lenz O, Borra S: Acute Renal Infarction: An Underdiagnosed Disorder. *J Med Cases* 3:197-200, 2012
5. Vodopivec D, Rubio JE, Fornoni A, Lenz O: An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. *Case Report Med*, Article ID 468452, 12 pages, 2012
6. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. *Clin J Am Soc Nephrol* 6:2688-2695, 2011
7. Porteous H, Morgan N, Lanfranco J, Garcia-Buitrago M, Young L, Lenz O. Systemic lupus erythematosus associated with type 4 renal tubular acidosis: a case report and review of the literature. *J Med Case Reports* 5(1):114, 2011.
8. Lenz O, Sancassani R, Bottino C, Fornoni A. Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report. *J Med Case Reports* 4:191, 2010
9. Salman L, Ladino M, Alex M, Dhamija R, Merrill D, Lenz O, Contreras G, Asif A Accuracy of ultrasound in the detection of inflow stenosis of arteriovenous fistulae: results of a prospective study. *Semin Dial* 23:117-121, 2010
10. Asif A, Salman L, Carrillo RG, Garisto JD, Lopera G, Barakat U, Lenz O, Yevzlin A, Agarwal A, Gadalean F, Sachdeva B, Vachharajani TJ, Wu S, Maya ID, Abreo K. Patency rates for angioplasty in the treatment of pacemaker-induced central venous stenosis in hemodialysis patients: results of a multi-center study. *Semin Dial* 22:671-676, 2009
11. Salman L, Alex M, Unger SW, Contreras G, Lenz O, Asif A. Secondary autogenous arteriovenous fistulas in the "fistula first" era: results of a longterm prospective study. *J Am Coll Surg* 209:100-105, 2009
12. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Saenz MO, Molano RD, Pileggi A, Ricordi C, Fornoni A: Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. *Kidney Int* 75:381-388, 2009
13. Leitao CB, Cure P, Messinger S, Pileggi A, Lenz O, Froud T, Faradji RN, Selvaggi G, Kupin W, Ricordi C, Alejandro R: Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. *Transplantation* 87:681-688, 2009
14. Tejada T, Catanuto P, Ijaz A, Santos JV, Xia X, Sanchez P, Sanabria N, Lenz O, Elliot SJ, Fornoni A. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. *Kidney Int* 73:1385-1393, 2008
15. Castro H, Valenzuela R, Ruiz P, Lenz O, Monrroy M: Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenstrom's Macroglobulinemia: a case report. *Cases J* 1:333, 2008
16. Asif A, Lenz O, Merrill D, Cherla G, Cipleu C, Ellis R, Francois B, Epstein DL, Pennell P. Percutaneous management of perianastomotic stenosis in arteriovenous fistulae. Results of a prospective study. *Kidney Int* 69:1904-1909, 2006
17. Fornoni A, Rosenzweig SA, Lenz O, Rivera A, Striker GE, Elliot SJ. Low IGFBP-2 expression is responsible for increased IRS-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis. *Endocrinology* 147:3547-54, 2006
18. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B. Outcomes in African Americans and Hispanics with lupus nephritis. *Kidney Int* 69:1904-1909, 2006
19. Lenz O, Sadhu S, Fornoni A, Asif A. Overutilization of Central Venous Catheters in Incident Hemodialysis Patients: Reasons and Potential Resolution Strategies. *Semin Dial* 19:543-550, 2006
20. Asif A, Besarab A, Gadalean F, Merrill D, Rismeyer AE, Contreras G, Leclercq B, Lenz O, Wallach J, Wallach J, Levine MI: Utility of Static Pressure Ratio recording during Angioplasty of Arteriovenous Graft Stenosis. *Semin Dial* 19: 551-557, 2006
21. Fornoni A, Lenz O: Chronic kidney disease care delivered by U.S. family medicine and internal medicine trainees: Results from an online survey. *BMC Medicine* 4:30, 2006
22. Lenz O, Mekala DP, Patel DV, Fornoni A, Metz D, Roth D. Barriers to successful care for chronic kidney disease. *BMC Nephrol* 6:11, 2005

23. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La CC, Iqbal K, Lenz O, Asif A, Nahar N, Leclercq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida SM, Busse JC, Esquenazi M, Esquenazi A, Garcia ML, Garcia EH. Factors associated with poor outcomes in patients with lupus nephritis. *Lupus* 14:890-895, 2005
24. Asif A, Unger SW, Briones P, Merrill D, Cherla G, Lenz O, Roth D, Pennell P. Creation of secondary arteriovenous fistulas: maximizing fistulas in prevalent hemodialysis patients. *Semin Dial* 18:420-424, 2005
25. Asif A, Cherla G, Merrill D, Cipleu CD, Tawakol JB, Epstein DL, Lenz O. Venous mapping using venography and the risk of radiocontrast-induced nephropathy. *Semin Dial* 18:239-242, 2005
26. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. *N Engl J Med* 350:971-980, 2004
27. Fornoni A, Lenz O, Striker LJ, Striker GE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. *Diabetes* 52:2594-2602, 2003
28. Fornoni A, Wang Y, Lenz O, Striker LJ, Striker GE. Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. *J Am Soc Nephrol* 13:2068-2076, 2002
29. Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, Karl M. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. *J Am Soc Nephrol* 12:241-251, 2001
30. Fornoni A, Lenz O, Tack I, Potier M, Elliot SJ, Striker LJ, Striker GE. Matrix accumulation in mesangial cells exposed to cyclosporine A requires a permissive genetic background. *Transplantation* 70:587-593, 2000
31. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. *Diabetes* 48:1638-1644, 1999
32. Lenz O, Zheng F, Vilar J, Doublier S, Lupia E, Schwedler S, Striker LJ, Striker GE. The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. *Nephrol Dial Transplant*. 13:3074-3078, 1998
33. Lenz O, Teichmann U, Langers A, Striker LJ, Striker GE, Pavan WJ. Linkage disequilibrium mapping reveals suppressed recombination at the Os locus. *Mamm Genome* 9:681-682, 1998
34. Lenz O, Striker LJ, Jacot TA, Elliot SJ, Killen PD, Striker GE. Glomerular endothelial cells synthesize collagens but little gelatinase A and B. *J Am Soc Nephrol* 9:2040-2047, 1998

Review Articles, Editorials, and Commentaries

1. Waheed AA, Pedraza F, Lenz O, Isakova T. Phosphate Control in End Stage Renal Disease: Barriers and Opportunities. *Nephrol Dial Transplant* 2013
2. Lenz O, Waheed A, Baig A, Pop A, Contreras G. Moving Points: Maintenance Therapy of Lupus Nephritis: Do we now have a plan? *Clin J Am Soc Nephrol* 8:162-171, 2013
3. Lenz O, Fornoni A. Proteinuria in diabetes: an endocrine disease? *Curr Diabetes Rev* 7:1-2, 2011
4. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in Diabetes: A Metabolic and Endocrine Disorder. *Am J Kidney Dis* 58:637-646, 2011
5. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras G. Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. *Lupus* 19:557-574, 2010
6. Ortega LM, Contreras G, Lenz O. Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn? *Nefrologia* 29:109-117, 2009
7. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. *Curr Diabetes Rev* 4:10-7, 2008
8. Kian K, Unger SW, Mishler R, Schon D, Lenz O, Asif A. Role of surgical intervention for cephalic arch stenosis in the "fistula first" era. *Semin Dial* 21:93-96, 2008
9. Lenz O, Fornoni A. Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center. *Kidney Int* 74:851-853, 2008
10. Tejada T, Fornoni A, Lenz O, Materson BJ. Combination therapy with renin-angiotensin blockers: will amlodipine replace hydrochlorothiazide? *Current Cardiol Rep* 9:284-290, 2007
11. Madhanasekaran V, Lenz O, Roth D. Maximizing Permanent Vascular Access Use in Hemodialysis Patients. *Touch Briefings, End-Stage Renal Disease – Vascular Access* 2007: 13-14, 2007
12. Asif A, Lenz O, Merrill D, Pennell P. What should nephrologists do to maximize the use of arteriovenous fistulas? *Semin Dial* 19(3):203-205, 2006.
13. Lenz O, Fornoni A, Contreras G. New directions in the management of severe lupus nephritis. *Minerva Urol Nefrol* 58:29-38, 2006

14. DeFreitas O, Lenz O, Fornoni A, Materson B. The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. *Vascular Health and Risk Management* 2:139-144, 2006
15. Tejada T, Fornoni A, Lenz O, Materson BJ. Nonpharmacologic therapy for hypertension: does it really work? *Curr Cardiol Rep* 8:418-424, 2006
16. Lenz O, Fornoni A, Contreras G. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. *Drugs* 65:2429-2436, 2005
17. Lenz O, Contreras G. Treatment options for severe lupus nephritis. *Arch Immunol Ther Exp* 52:356-365, 2004
18. Raij L, Madias NE, Lenz O, Epstein M, Jaimes EA, Materson BJ, Banerjee D, Preston RA, Roth D, Abraira C. End-organ susceptibility as a determinant of renal disease in hypertension. *Kidney Int* 64: 1923-1932, 2003
19. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. *J Am Soc Nephrol* 11:574-581, 2000

Book Chapters

1. Ortega L, Lenz O: Metabolic alkalosis. In: *Clinical Decision Making in Nephrology, Hypertension, and Kidney Transplantation* by Edgar Lerma and Mitchell Rosner (eds.), Springer (New York) 2013
2. Lenz O: Mixed acid-base disorders. In: *Clinical Decision Making in Nephrology, Hypertension, and Kidney Transplantation* by Edgar Lerma and Mitchell Rosner (eds.), Springer (New York) 2013
3. Oshiro Mocelin DeCarvalho C, Ortega L, Lenz O, Schulz D, Contreras G. Nefrite Lúpica. In: *Discutindo casos clínicos: Doenças renais* by Gianna Mastroianni Kirsztaju (ed.), Livraria Balieiro, São Paolo, Brazil, 1st edition, 2012